I'm LongbridgeAI, I can summarize articles.CMBI issued a research report stating that the US Food and Drug Administration (FDA) declined to approve ivonescimab combined with chemotherapy for second-line EGFR-mutated non-small cell lung cancer (NSCLC), believing that while progression-free survival (PFS) improved, overall survival (OS) did not reach statistical significance and therefore failed to establish a positive benefit-risk profile. The broker maintained its "Buy" rating on AKESO (09926.HK) -2.900 (-4.685%) Short selling $204.82M; Ratio 24.236% and, based on DCF valuation, lowered its TP by 28.2% from HKD138.42 to HKD99.34.
The broker noted that although the global HARMONi trial achieved significant PFS improvement, the primary OS analysis did not reach significance (hazard ratio of 0.79, p=0.057). Subsequent longer follow-up showed OS hazard ratios of 0.76 for the overall, Asian and Western populations, but these were post-hoc analyses and insufficient to change the FDA's assessment. Second-line EGFR-mutated NSCLC is a relatively small indication, accounting for less than 5% of the broker's estimate of ivonescimab's global peak sales, while the limitations of HARMONi cannot be directly extrapolated to the broader Summit development program.
The broker believes HARMONi-3 is more critical in determining whether ivonescimab can outperform existing standard therapies in large indications. The trial was specifically designed as a multi-regional first-line study, with statistical power established separately for squamous and non-squamous cohorts. The required number of PFS events for the primary analysis of the squamous cohort is expected to be reached in 4Q26, alongside a planned early interim OS analysis. The PFS event threshold for the non-squamous cohort is expected to be reached in 1H27.
The broker said the Complete Response Letter (CRL) will delay US commercialization, while HARMONi-3 and successful combination therapy trials remain central to the investment thesis for AKESO. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-18 12:25.)
